Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive”

202 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 202 results

Testing effectiveness (Phase 2)Study completedNCT03046992
What this trial is testing

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

Who this might be right for
EGFR Gene Mutation
Yuhan Corporation 224
Early research (Phase 1)UnknownNCT05826483
What this trial is testing

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Who this might be right for
Malignant Tumor of LungPoor Performance Status
Guangzhou Institute of Respiratory Disease 20
Testing effectiveness (Phase 2)UnknownNCT02906163
What this trial is testing

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Who this might be right for
EGFR Mutation Positive Non Small Cell Lung Cancer
SciClone Pharmaceuticals 188
Large-scale testing (Phase 3)UnknownNCT03008109
What this trial is testing

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Who this might be right for
Advanced CancerLung Cancer, Nonsmall Cell
Zaiwen Fan 80
Not applicableUnknownNCT03071705
What this trial is testing

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

Who this might be right for
Non-Small Cell AdenocarcinomaTyrosine Kinase MutationEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico 120
Post-approval studies (Phase 4)Ended earlyNCT02299765
What this trial is testing

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Sichuan University 61
Testing effectiveness (Phase 2)UnknownNCT03382795
What this trial is testing

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
Korea University Guro Hospital 63
Testing effectiveness (Phase 2)UnknownNCT01410214
What this trial is testing

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer Stage IIIA
Chinese Lung Cancer Surgical Group 80
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Testing effectiveness (Phase 2)Study completedNCT01982955
What this trial is testing

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Who this might be right for
Non-small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany 88
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Not applicableEnded earlyNCT02932345
What this trial is testing

Gefitinib Long-term Survivor Study

Who this might be right for
EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
AstraZeneca 59
Early research (Phase 1)Ended earlyNCT03054038
What this trial is testing

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Carcinoma
Vanderbilt-Ingram Cancer Center 22
Testing effectiveness (Phase 2)Ended earlyNCT01953926
What this trial is testing

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Who this might be right for
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc. 582
Testing effectiveness (Phase 2)Looking for participantsNCT06631989
What this trial is testing

Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc. 100
Testing effectiveness (Phase 2)Study completedNCT02804776
What this trial is testing

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

Who this might be right for
Non-small Cell Lung Cancer
National Cancer Centre, Singapore 15
Testing effectiveness (Phase 2)Looking for participantsNCT06775743
What this trial is testing

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University 53
Large-scale testing (Phase 3)UnknownNCT04239833
What this trial is testing

SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 240
Not applicableStudy completedNCT03219970
What this trial is testing

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 156
Testing effectiveness (Phase 2)Active Not RecruitingNCT04504071
What this trial is testing

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGF-R Positive Non-Small Cell Lung Cancer
Shanghai Chest Hospital 30
Next Page